Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eagle Pharmaceuticals (NQ: EGRX )

4.300 -0.070 (-1.60%)
Streaming Delayed Price Updated: 9:30 AM EDT, May 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eagle Pharmaceuticals

< Previous 1 2 Next >
Eagle Pharma Adds Hospital-Based Products With €95M Acacia Pharma Deal
Eagle Pharmaceuticals Inc (NASDAQ: EGRX) has agreed to acquire Acacia Pharma Group plc  
Via Benzinga
Eagle Pharma's Q4 Earnings Miss Street View On Lower Product Sales
Eagle Pharmaceuticals Inc's (NASDAQ: EGRX) Q4 FY21 sales declined 15% Y/Y to $42.3 million, missing the consensus of $51.08 million. The sales declined primarily... 
Via Benzinga
Eagle Pharmaceuticals: Q4 Earnings Insights
Eagle Pharmaceuticals (NASDAQ:EGRX) reported its Q4 earnings results on Monday, March 7, 2022 at 06:50 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
Earnings Scheduled For March 7, 2022
Companies Reporting Before The Bell • Niu Technologies (NASDAQ:NIU) is expected to report quarterly earnings at $0.21 per share on revenue of $144.02 million. •... 
Via Benzinga
Eagle Pharmaceuticals's Earnings Outlook
Eagle Pharmaceuticals (NASDAQ:EGRX) is set to give its latest quarterly earnings report on Monday, 2022-03-07. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
Earnings Scheduled For May 10, 2021
Companies Reporting Before The Bell • Revlon (NYSE:REV) is likely to report earnings for its first quarter. • Bluegreen Vacations (NYSE:BVH) is expected to report... 
Via Benzinga
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (... 
Via Benzinga
The Daily Biotech Pulse: Lilly Raises Guidance, Medtronic Gets FDA Warning Letter, Decision Day For Calliditas, Genenta IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Vir Biotech Says COVID-19 Antibody Treatment Effective Against Omicron... 
Via Benzinga
The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More
Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound. Multiple... 
Via Benzinga
Exposures Product Safety
Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates
A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for... 
Via Benzinga
Exposures Product Safety
Eagle Pharmaceuticals, inc (EGRX) Q3 2021 Earnings Call Transcript
EGRX earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
33 Stocks Moving In Tuesday's Mid-Day Session
Gainers AC Immune SA (NASDAQ: ACIU) shares jumped 68.4% to $11.77. AC Immune and its collaborating partner Genentech, part of Roche Holdings, announced topline data from Phase 2... 
Via Benzinga
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug
ere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (... 
Via Benzinga
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
Exposures Product Safety
Eagle Pharmaceuticals, inc (EGRX) Q2 2021 Earnings Call Transcript
EGRX earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (... 
Via Benzinga
Eagle Pharmaceuticals In-Licenses US Rights For Emergency Hospital Product, Q2 Earnings Beat Consensus
Eagle Pharmaceuticals Inc (NASDAQ: EGRX) has entered into a licensing agreement with AOP Orphan Pharmaceuticals GmbH for the commercial rights to its product,... 
Via Benzinga
Topics Earnings
Exposures Financial
Recap: Eagle Pharmaceuticals Q2 Earnings
Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share were up 63.16% year over year to $0... 
Via Benzinga
The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31) AC Immune SA (NASDAQ: ACIU... 
Via Benzinga
Eagle Pharmaceuticals: Return On Capital Employed Insights
During Q1, Eagle Pharmaceuticals (NASDAQ:EGRX) brought in sales totaling $41.25 million. However, earnings decreased 138.53%, resulting in a loss of $3.77 million. In Q4, Eagle... 
Via Benzinga
Return On Capital Employed Overview: Eagle Pharmaceuticals
During Q1, Eagle Pharmaceuticals (NASDAQ:EGRX) brought in sales totaling $41.25 million. However, earnings decreased 138.53%, resulting in a loss of $3.77 million. Eagle... 
Via Benzinga
55 Biggest Movers From Yesterday
Gainers Unico American Corporation (NASDAQ: UNAM) shares gained 59% to close at $4.15 on Tuesday. Elys Game Technology, Corp. (NASDAQ: ELYS) rose 43% to close at $6.62 after it... 
Via Benzinga
Eagle Pharmaceuticals Inc (EGRX) Q1 2021 Earnings Call Transcript
EGRX earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Recap: Eagle Pharmaceuticals Q1 Earnings
Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share decreased 71.43% year over... 
Via Benzinga
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
Via Benzinga
Exposures COVID-19 Product Safety
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Reviva Pharmaceuticals (NASDAQ:RVPH) shares rose 72.91% to $7.47 during Monday's regular session. Reviva Pharmaceuticals's stock is trading at a volume of... 
Via Benzinga
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.